Cancer genomic medicine in Japan and the roles of pharmacists.

IF 1.7 3区医学 Q4 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Pharmacogenetics and genomics Pub Date : 2022-08-01 DOI:10.1097/FPC.0000000000000476

Tohru Aomori, Hiroomi Sakurai, Hiroshi Nishihara

引用次数: 1

Abstract

Cancer genomic medicine (CGM) is a medical service that provides optimized treatment for each patient based on genes, biomarkers, environment, and lifestyle. In Japan, the approval of designed core hospitals for CGM started in 2017. In June 2019, two types of cancer gene panel tests became available in the national health insurance system, and CGM was socially implemented. While CGM is still in its infancy and there are some issues that need to be resolved, there are cases where the treatment has shown dramatic results. The present review highlights the CGM system in Japan, the issues it faces, and the role of pharmacists in this system.

查看原文本刊更多论文

日本的癌症基因组医学和药剂师的角色。

癌症基因组医学(Cancer genomic medicine, CGM)是一种基于基因、生物标志物、环境和生活方式为每位患者提供优化治疗的医疗服务。在日本，2017年开始批准CGM设计的核心医院。2019年6月，两种类型的癌症基因检测纳入国民健康保险体系，并在社会上实施了CGM。虽然CGM仍处于起步阶段，还有一些问题需要解决，但在某些情况下，这种治疗已经显示出显著的效果。本文重点介绍了日本的CGM制度、面临的问题以及药剂师在这一制度中的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacogenetics and genomics 医学-生物工程与应用微生物

CiteScore

3.20

自引率

3.80%

发文量

审稿时长

3 months

期刊介绍： Pharmacogenetics and Genomics is devoted to the rapid publication of research papers, brief review articles and short communications on genetic determinants in response to drugs and other chemicals in humans and animals. The Journal brings together papers from the entire spectrum of biomedical research and science, including biochemistry, bioinformatics, clinical pharmacology, clinical pharmacy, epidemiology, genetics, genomics, molecular biology, pharmacology, pharmaceutical sciences, and toxicology. Under a single cover, the Journal provides a forum for all aspects of the genetics and genomics of host response to exogenous chemicals: from the gene to the clinic.